A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

Conclusion This trial supports ubrogepant’s efficacy and provides further evidence that CGRP-RAs are viable options for the acute treatment of migraine.

http://cep.sagepub.com/cgi/content/abstract/36/9/887?rss=1

Source: Cephalalgia - July 21, 2016 Category: Neurology Authors: Voss, T., Lipton, R. B., Dodick, D. W., Dupre, N., Ge, J. Y., Bachman, R., Assaid, C., Aurora, S. K., Michelson, D. Tags: Original Articles Source Type: research